即刻假体乳房重建术后晚期手术部位感染
基于乳房切除重建结局联盟研究,评估1024例患者共1662例次即刻假体乳房重建的早期与晚期手术部位感染。组织扩张器重建一期感染率5.7%、二期2.5%,直接假体9.9%,其中47%至71%为晚期感染;放疗与体重指数升高是晚期感染的显著预测因素。
要点
- 即刻假体乳房重建的感染多数发生在术后30天之后
- 放疗与体重指数升高与晚期手术部位感染显著相关
- 直接假体与组织扩张器组的早期、晚期及总体感染无显著差异
核心结论
- 即刻假体乳房重建的手术部位感染并发症多数发生于一期和二期手术30天之后。
- 放疗与肥胖(体重指数升高)与晚期起病的感染显著相关。
- 仅关注早期并发症的研究不能完整评估假体乳房重建相关感染及长期结局。
研究设计与样本
- 乳房切除重建结局联盟研究(Mastectomy Reconstruction Outcomes Consortium Study)的一部分。
- 纳入1024例患者的1662例次假体乳房重建,比较早期与晚期手术部位感染。
- 早期感染定义为术后30天内发生,晚期定义为术后31天至1年发生;轻度感染仅需口服抗生素,重度需住院和/或手术处理。
- 直接假体患者随访1年,组织扩张器患者随访至换假体后1年。
主要发现
- 组织扩张器重建一期术后总体手术部位感染率为5.7%(85/1491)。
- 组织扩张器重建二期术后感染率为2.5%(31/1266)。
- 直接假体重建感染率为9.9%(17/171)。
- 47%至71%的手术部位感染并发症为晚期感染。
- 多因素分析显示放疗与体重指数升高是晚期手术部位感染的显著预测因素;直接假体与组织扩张器组在早期、晚期或总体感染上无显著差异。
临床怎么用
- 假体乳房重建术后随访应覆盖至术后1年,不能仅局限于30天。
- 对接受放疗或体重指数较高的患者应加强晚期感染的监测与防范。
局限性
- 原文摘要未报告具体局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical-site infection causes devastating reconstructive failure in implant-based breast reconstructions. Large national database studies offer insights into complication rates, but only capture outcomes within 30 days postoperatively. This study evaluates both early and late surgical-site infection in immediate implant-based reconstruction and identifies predictors. METHODS: As part of the Mastectomy Reconstruction Outcomes Consortium Study, 1662 implant-based breast reconstructions in 1024 patients were evaluated for early versus late surgical-site infection. Early surgical-site infection was defined as infection occurring within 30 days postoperatively; late surgical-site infection was defined as infection occurring 31 days to 1 year postoperatively. Minor infection required oral antibiotics only, and major infection required hospitalization and/or surgical treatment. Direct-to-implant patients had 1-year follow-up, and tissue expander patients had 1-year post-exchange follow-up. RESULTS: Among 1491 tissue expander and 171 direct-to-implant reconstructions, overall surgical-site infection rate for tissue expander was 5.7 percent (85 of 1491) after first-stage, 2.5 percent (31 of 1266) after second-stage, and 9.9 percent (17 of 171) for direct-to-implant reconstruction. Over 47 to 71 percent of surgical-site infection complications were late surgical-site infection. Multivariate analysis identified radiotherapy and increasing body mass index as significant predictors of late surgical-site infection. No significant difference between the direct-to-implant and tissue expander groups in the occurrence of early, late, or overall surgical-site infection was found. CONCLUSIONS: The majority of surgical-site infection complications in immediate implant-based breast reconstructions occur more than 30 days after both first-stage and second-stage procedures. Radiotherapy and obesity are significantly associated with late-onset surgical-site infection. Current studies limited to early complications do not present a complete assessment of infection associated with implant-based breast reconstructions or their long-term clinical outcomes. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
引用
- Sinha I, Pusic AL, Wilkins EG, et al. Late Surgical-Site Infection in Immediate Implant-Based Breast Reconstruction. Plast Reconstr Surg. 2017. PMID: 28027221. doi:10.1097/PRS.0000000000002839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。